What is Modulus Therapeutics?
Modulus Therapeutics is at the forefront of revolutionizing cell therapy for autoimmune conditions. The company leverages innovative rapid prototyping and generative design to create off-the-shelf CAR-NK therapies, aiming to enhance safety and accessibility compared to existing CAR-T treatments. Their proprietary platform enables the crafting of custom CARs and switch receptors, boosting the efficacy of immune cell therapies while streamlining the preparation process. This advanced approach positions Modulus Therapeutics as a key innovator in the burgeoning field of regenerative medicine, targeting autoimmune patients with novel therapeutic options.
How much funding has Modulus Therapeutics raised?
Modulus Therapeutics has raised a total of $3.5M across 1 funding round:
Angel/Seed
$3.5M
Angel/Seed (2021): $3.5M with participation from Ai2, Madrona Venture Group, and KdT Ventures
Key Investors in Modulus Therapeutics
Ai2
Ai2 is focused on preventing medical device infections through peptide coatings, offering a non-cytotoxic and cost-effective solution that is highly efficacious and resistant to microbial resistance, positioning them as a key player in the anti-infective medical device sector.
Madrona Venture Group
Madrona Venture Group, established in 1995, is a venture capital firm that invests in consumer internet, commercial software, and services.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science, focusing on transformative technologies in medicine, chemicals, and materials, often leading pre-seed and seed rounds.
What's next for Modulus Therapeutics?
The recent major strategic investment in Modulus Therapeutics signals a pivotal growth phase for the company. This capital infusion is expected to accelerate the development and clinical validation of their innovative cell therapy platform. With a focus on overcoming the limitations of current treatments for autoimmune diseases, Modulus Therapeutics is poised to expand its market reach and solidify its position as a leader in accessible and effective cell-based immunotherapies. Future endeavors will likely involve scaling production, forging strategic partnerships, and advancing their pipeline through further clinical trials.
See full Modulus Therapeutics company page
